A carregar...
(89)Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
Background: Despite the improvement in clinical outcomes for head and neck squamous cell carcinoma (HNSCC) as the result of cetuximab, patients may present with or develop resistance that increases tumor recurrence rates and limits clinical efficacy. Therefore, identifying those patients who are or...
Na minha lista:
| Publicado no: | Cancer Biother Radiopharm |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Mary Ann Liebert, Inc., publishers
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6588098/ https://ncbi.nlm.nih.gov/pubmed/30865493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2018.2616 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|